Cirsium Biosciences

Cirsium Biosciences is on a mission to revolutionize gene therapy manufacturing by leveraging the power of plants. Their innovative platform uses transient gene expression in plants grown in Controlled Environment Agriculture (CEA) to produce high-quality AAV vectors, promising a 70% reduction in manufacturing lead times and significant cost savings compared to traditional methods. The company is a private, pre-clinical stage platform technology firm focused on developing and scaling its production systems to address the severe capacity constraints in the gene therapy supply chain. Their team of scientists and executives is dedicated to improving global patient access to life-saving genetic medicines.

A plant-based biopharming platform that uses whole plants as bioreactors within Controlled Environment Agriculture (CEA) to produce adeno-associated virus (AAV) vectors for gene therapy via transient agroinfiltration.

Total raised: $2M

Cirsium competes against traditional viral vector CDMOs using mammalian/insect cells (e.g., Lonza, Catalent) and other novel platform companies. Its main differentiation is the potential for radical cost reduction and linear scalability using plants as bioreactors, a fundamentally different approach from capital-intensive fermentation-based systems.